Literature DB >> 27074425

Imaging of Cystic Fibrosis Lung Disease and Clinical Interpretation.

M O Wielpütz1, M Eichinger1, J Biederer1, S Wege2, M Stahl3, O Sommerburg3, M A Mall3, H U Kauczor1, M Puderbach1.   

Abstract

UNLABELLED: Progressive lung disease in cystic fibrosis (CF) is the life-limiting factor of this autosomal recessive genetic disorder. Increasing implementation of CF newborn screening allows for a diagnosis even in pre-symptomatic stages. Improvements in therapy have led to a significant improvement in survival, the majority now being of adult age. Imaging provides detailed information on the regional distribution of CF lung disease, hence longitudinal imaging is recommended for disease monitoring in the clinical routine. Chest X-ray (CXR), computed tomography (CT) and magnetic resonance imaging (MRI) are now available as routine modalities, each with individual strengths and drawbacks, which need to be considered when choosing the optimal modality adapted to the clinical situation of the patient. CT stands out with the highest morphological detail and has often been a substitute for CXR for regular severity monitoring at specialized centers. Multidetector CT data can be post-processed with dedicated software for a detailed measurement of airway dimensions and bronchiectasis and potentially a more objective and precise grading of disease severity. However, changing to CT was inseparably accompanied by an increase in radiation exposure of CF patients, a young population with high sensitivity to ionizing radiation and lifetime accumulation of dose. MRI as a cross-sectional imaging modality free of ionizing radiation can depict morphological hallmarks of CF lung disease at lower spatial resolution but excels with comprehensive functional lung imaging, with time-resolved perfusion imaging currently being most valuable. KEY POINTS: • Hallmarks are bronchiectasis, mucus plugging, air trapping, perfusion abnormalities, and emphysema.• Imaging is more sensitive to disease progression than lung function testing.• CT provides the highest morphological detail but is associated with radiation exposure.• MRI shows comparable sensitivity for morphology but excels with additional functional information.• MRI sensitively depicts reversible abnormalities such as mucus plugging and perfusion abnormalities. Citation Format: • Wielpütz MO, Eichinger M, Biederer J et al. Imaging of Cystic Fibrosis Lung Disease and Clinical Interpretation. Fortschr Röntgenstr 2016; 188: 834 - 845. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 27074425     DOI: 10.1055/s-0042-104936

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  21 in total

Review 1.  Ten years of chest MRI for patients with cystic fibrosis : Translation from the bench to clinical routine.

Authors:  Patricia Leutz-Schmidt; Monika Eichinger; Mirjam Stahl; Olaf Sommerburg; Jürgen Biederer; Hans-Ulrich Kauczor; Michael U Puderbach; Marcus A Mall; Mark O Wielpütz
Journal:  Radiologe       Date:  2019-12       Impact factor: 0.635

2.  Structural and perfusion magnetic resonance imaging of the lung in cystic fibrosis.

Authors:  Christina Amaxopoulou; Ralph Gnannt; Kai Higashigaito; Andreas Jung; Christian J Kellenberger
Journal:  Pediatr Radiol       Date:  2017-11-15

3.  [Clinical and gene mutation features of cystic fibrosis: an analysis of 8 cases].

Authors:  Na Zhang; Jian-Hua Liu; Ya-Juan Chu; Jin-Feng Shuai; Kun-Ling Huang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-07-15

4.  Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study.

Authors:  Giuseppe Migliorisi; Mirella Collura; Francesca Ficili; Tiziana Pensabene; Dafne Bongiorno; Antonina Collura; Francesca Di Bernardo; Stefania Stefani
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-14

Review 5.  Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential.

Authors:  Michael C McKelvey; Sinéad Weldon; Daniel F McAuley; Marcus A Mall; Clifford C Taggart
Journal:  Am J Respir Crit Care Med       Date:  2020-01-15       Impact factor: 21.405

Review 6.  Current state of the art MRI for the longitudinal assessment of cystic fibrosis.

Authors:  Jason C Woods; Jim M Wild; Mark O Wielpütz; John P Clancy; Hiroto Hatabu; Hans-Ulrich Kauczor; Edwin J R van Beek; Talissa A Altes
Journal:  J Magn Reson Imaging       Date:  2019-12-17       Impact factor: 4.813

Review 7.  Novel imaging techniques for cystic fibrosis lung disease.

Authors:  Jennifer L Goralski; Neil J Stewart; Jason C Woods
Journal:  Pediatr Pulmonol       Date:  2021-02

8.  Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis.

Authors:  Neeraj Vij
Journal:  J Pers Med       Date:  2021-02-03

Review 9.  Practical protocol for lung magnetic resonance imaging and common clinical indications.

Authors:  Kushaljit Singh Sodhi; Pierluigi Ciet; Shreyas Vasanawala; Juergen Biederer
Journal:  Pediatr Radiol       Date:  2021-05-26

Review 10.  Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis.

Authors:  Mirjam Stahl; Eva Steinke; Marcus A Mall
Journal:  Genes (Basel)       Date:  2021-05-25       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.